SWOG

Guardant's test will be used to detect mutations associated with acquired resistance to EGFR-inhibiting therapies and to guide further treatment strategies in a study of 600 patients.

The funding will support the creation of biorepositories, biomarker discovery and validation, and personalized cancer therapeutic clinical trials.

The Center for Comparative Effectiveness Research in Cancer Genomics expects its first clinical trial, which is investigating the predictive value of Genomic Health's Oncotype Dx in node-positive breast cancer patients, to serve as a model for future comparative effectiveness studies looking at genomic technologies in cancer.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.